respiratori
virus
one
major
caus
concern
among
public
health
author
scientist
deal
health
issu
threat
pose
virus
like
influenza
viru
respiratori
syncyti
viru
rsv
sever
acut
respiratori
syndrom
sar
viru
well
understood
varieti
strategi
develop
counter
virus
human
metapneumoviru
hmpv
identifi
scientist
netherland
yet
anoth
respiratori
viru
abil
caus
mild
sever
diseas
peopl
age
group
especi
children
year
age
account
lower
respiratori
tract
infect
lrti
despit
sever
research
vaccin
therapi
yet
commerci
take
care
hmpv
infect
review
focus
differ
prophylact
therapeut
approach
investig
till
date
human
metapneumoviru
hmpv
belong
metapneumoviru
genu
pneumovirida
famili
creat
member
famili
includ
avian
metapneumoviru
ampv
human
respiratori
syncyti
viru
hrsv
bovin
respiratori
syncyti
viru
brsv
murin
pneumonia
viru
mpv
envelop
viru
neg
sens
singl
strand
nonseg
rna
genom
length
nucleotid
genom
contain
eight
gene
encod
nine
protein
order
flank
leader
sequenc
end
trailer
sequenc
end
fig
leader
header
sequenc
role
replic
transcript
viral
genom
nucleoprotein
n
phosphoprotein
p
matrix
protein
rna
depend
rna
polymeras
l
get
associ
rna
genom
form
rna
polymeras
complex
carri
viral
replic
transcript
virion
surfac
show
presenc
three
glycoprotein
viz
small
hydrophob
sh
protein
heavili
glycosyl
g
protein
fusion
f
protein
fig
g
f
protein
role
fusion
entri
viru
host
cell
heparan
sulphat
proteoglycan
receptor
role
sh
protein
complet
understood
studi
claim
help
viru
evad
host
antivir
immun
respons
downregul
type
ifn
signal
also
role
regul
host
membran
permeabl
matrix
protein
form
layer
beneath
viru
envelop
role
viru
assembl
bud
two
protein
viz
encod
second
gene
protein
enhanc
process
rna
depend
rna
polymeras
rdrp
requir
full
length
synthesi
viral
mrna
protein
maintain
balanc
viral
genom
replic
transcript
host
cytoplasm
two
genotyp
hmpv
observ
clinic
isol
report
till
date
b
divid
five
genet
lineag
classif
done
basi
variabl
membran
glycoprotein
viru
protein
level
f
protein
highli
conserv
type
hmpv
sequenc
ident
g
protein
highli
diverg
sequenc
ident
subtyp
hmpv
worldwid
distribut
peak
activ
coincid
peak
rsv
activ
although
viru
circul
throughout
year
predomin
late
winter
spring
diseas
sever
also
vari
mild
respiratori
symptom
sever
pneumonia
ultim
depend
factor
like
age
child
presenc
chronic
ailment
studi
done
univers
hospit
trondheim
norway
approxim
children
hospit
lrti
diagnos
hmpv
infect
observ
children
born
prematur
chronic
airway
diseas
like
asthma
prone
infect
hmpv
relat
respiratori
virus
like
rsv
age
child
also
correl
diseas
sever
child
age
month
show
sever
symptom
compar
age
group
conclud
matern
antibodi
play
signific
role
protect
child
month
age
apart
children
hmpv
infect
observ
peopl
age
group
though
lower
rate
adult
lrti
posit
hmpv
infect
seroepidemiolog
studi
show
almost
adult
across
world
seroposit
respect
one
strain
hmpv
similar
observ
record
yet
anoth
studi
involv
subject
northern
southern
hemispher
observ
burden
hmpv
significantli
higher
northern
hemispher
compar
southern
hemispher
howev
differ
diseas
sever
due
strain
variat
clear
vari
consider
knowledg
host
immun
respons
hmpv
infect
requir
understand
immunopatholog
induc
viru
develop
vaccin
therapeut
like
viru
innat
adapt
immun
compon
essenti
clear
hmpv
infect
induc
weak
memori
respons
host
innat
immun
respons
first
line
defenc
viral
infect
act
recogn
pathogen
associ
molecular
pattern
pamp
viral
particl
pattern
recognit
receptor
prr
present
immun
cell
respiratori
tract
common
prr
like
membran
bound
tolllikereceptor
tlr
ctype
lectin
receptor
clr
cytoplasm
rigi
like
receptor
rlr
nucleotidebind
oligomer
domain
nod
like
receptor
nlr
recogn
viral
pamp
initi
inflammatori
immun
respons
via
cytokin
produc
cell
respiratori
tract
common
adaptor
tlr
mediat
pathway
shown
essenti
pulmonari
immun
respons
hmpv
infect
recruit
immun
cell
lung
howev
hmpv
g
protein
import
role
inhibit
innat
immun
respons
target
rigi
host
cell
cytoplasm
hand
adapt
immun
highli
viru
specif
hmpv
infect
protect
humor
immun
mostli
direct
toward
f
protein
viru
rather
g
sh
protein
cell
mediat
immun
respons
majorli
respons
immun
surveil
infect
host
clear
viru
infect
activ
viru
specif
cytotox
lymphocyt
ctl
induc
apoptosi
infect
cell
activ
th
cell
activ
b
cell
immun
cell
like
dc
macrophag
studi
done
mice
model
indic
hmpv
primari
infect
well
cell
respons
inflamm
bodi
weight
loss
lead
sever
lung
diseas
also
protect
role
clear
viru
infect
host
bodi
evid
accumul
hmpv
specif
ctl
lung
infect
host
approxim
day
post
infect
hmpv
infect
elderli
host
skew
respons
seem
caus
aggrav
lung
diseas
howev
cell
deplet
infect
less
sever
cell
alon
effect
clear
viru
infect
interestingli
also
demonstr
one
recent
studi
express
pattern
inhibitor
receptor
program
program
death
hmpv
infect
lead
impair
cell
respons
contribut
hmpv
reinfect
immunocompet
host
show
antivir
immun
respons
elimin
viru
infect
viru
hand
evad
host
immun
respons
mechan
specif
viru
unlik
rsv
hmpv
nonstructur
protein
evad
host
innat
immun
respons
via
g
sh
protein
protein
hmpv
specif
respons
immun
evas
block
interact
mitochondri
antivir
signal
protein
mav
downstream
tnf
receptor
associ
factor
traf
although
seroepidemiolog
studi
reveal
individu
infect
hmpv
age
year
repeat
infect
viru
common
throughout
life
may
due
diminish
immun
viral
antigen
host
restrict
crossreact
antibodi
nucleosid
analogu
na
antimetabolit
mimic
physiolog
nucleosid
get
incorpor
newli
synthes
dna
block
dna
synthesi
lead
chain
termin
sever
na
assess
antivir
agent
ribavirin
one
na
effect
pneumovirus
vitro
vivo
use
treat
case
hmpv
infect
also
apart
inhibit
viral
rna
synthesi
ribavirin
modul
host
immun
system
upregul
secret
helper
th
cytokin
like
etc
cell
downregul
secret
cytokin
like
help
restrict
viral
pathogenesi
absenc
experiment
proof
till
date
suggest
ribavirin
may
given
treat
hmpv
infect
aerosol
dose
recommend
contain
rsv
infect
howev
aerosolis
drug
limit
like
high
cost
teratogen
potenti
weaken
respiratori
function
ribavirin
also
use
intraven
iv
rout
combin
intraven
immunoglobulin
ivig
treat
hmpv
infect
result
quit
contradictori
doko
et
al
park
et
al
observ
effect
iv
ribavirin
combin
ivig
signific
treat
hmpv
infect
author
report
iv
ribavirinor
ribavirin
combin
ivig
could
success
treat
infect
differ
categori
patient
fusion
viral
envelop
host
cell
membran
via
hmpv
f
protein
import
initi
viral
infect
peptid
capabl
inhibit
fusion
event
potenti
reduc
viru
replic
infect
host
deffrasn
et
al
identifi
peptid
deriv
heptad
repeat
domain
hmpv
f
protein
assess
effect
reduc
morbid
mortal
caus
viru
one
peptid
found
effect
reduc
lung
viral
load
pulmonari
inflamm
airway
obstruct
level
proinflammatori
cytokineschemokin
treat
balbc
mice
peptid
express
nicotiana
tabacum
shown
inhibit
bind
viru
cell
vitro
condit
studi
need
done
evalu
efficaci
peptid
express
plant
system
inhibit
viru
infect
anim
model
recent
fusion
inhibitor
report
rsv
anoth
pneumoviru
close
relat
hmpv
need
search
small
molecul
fusion
inhibitor
may
potenti
bind
hmpv
f
protein
also
prefus
conform
prevent
viru
infect
host
cell
sulfat
sialyl
lipid
shown
potent
antivir
activ
hmpv
spetch
et
al
assess
effect
treatment
hmpv
infect
treatment
balbc
mice
one
dose
mg
bodi
weight
time
infect
significantli
reduc
lung
viral
load
also
reduc
recruit
inflammatori
cell
lung
clinic
ill
level
proinflammatori
cytokineschemokin
lung
also
significantli
reduc
treatment
specul
addit
antivir
effect
inhibit
viral
entri
replic
host
cell
also
antiinflammatori
effect
recipi
host
rna
interfer
use
small
interf
rna
sirna
short
hairpin
rna
shrna
use
sinc
long
time
specif
silenc
target
gene
therapeut
approach
hmpv
darniot
et
al
deffrasn
et
al
demonstr
efficaci
sirna
specif
viral
gene
encod
nucleoprotein
n
phosphoprotein
p
darniot
et
al
show
modifi
sirna
target
conserv
region
hmpv
nucleocapsid
mrna
could
partial
inhibit
viral
replic
confirm
offtarget
effect
sirna
also
cytokin
contribut
inhibitori
effect
deffrasn
et
al
previous
identifi
two
potent
sirna
n
gene
p
gene
demonstr
efficaci
strain
four
subgroup
hmpv
g
gene
hmpv
also
target
preston
et
al
downregul
result
reduct
viral
growth
signific
increas
type
interferon
express
observ
monoclon
antibodi
direct
conserv
epitop
immunogen
protein
viru
abil
protect
minim
diseas
sever
infect
individu
efficaci
prophylaxi
palivizumab
monoclon
antibodi
previous
shown
rsv
infect
high
risk
group
fusion
protein
hmpv
highli
immunogen
conserv
among
variou
type
subtyp
viru
recent
human
monoclon
antibodi
direct
conserv
epitop
hmpv
fusion
protein
shown
highli
neutral
effect
decreas
viral
titr
lung
nasal
aspir
infect
hmpv
permiss
mice
model
prophylact
therapeut
efficaci
compar
palivizumab
wrt
viral
titr
nasal
aspir
better
palivizumab
wrt
titr
lung
homogen
prior
fab
recombin
human
monoclon
antibodi
fragment
gener
use
phage
display
technolog
fusion
protein
epitop
evalu
found
significantli
effect
restrict
propag
hmpv
lung
cotton
rat
even
ulbrandt
et
al
gener
panel
monoclon
antibodi
f
protein
anim
model
two
mab
viz
mab
mab
effect
almost
four
subtyp
hmpv
specul
human
optim
two
mab
could
give
better
result
human
individu
et
al
also
gener
two
mous
monoclon
antibodi
f
protein
hmpv
demonstr
neutral
capac
viru
infect
cell
recent
replic
transcript
hmpv
bronchial
epithelialderiv
immort
cell
analyz
deduc
like
filovirus
rhabdovirus
format
cytoplasm
inclus
bodi
requir
hmpv
genom
replic
transcript
understand
mechan
pathway
format
inclus
bodi
may
give
crucial
lead
develop
new
therapeut
current
also
work
develop
ribozym
base
therapeut
base
conserv
natur
fusion
nucleoprotein
viru
data
publish
yet
inactiv
vaccin
success
manag
sever
viral
infect
like
influenza
polio
etc
vaccin
stabl
biolog
safe
howev
efficaci
type
vaccin
vari
viru
method
use
viral
inactiv
significantli
affect
immun
respons
demonstr
vaccin
formalin
inactiv
hmpv
lead
enhanc
diseas
sever
upon
challeng
wild
type
viru
could
attribut
enhanc
pulmonari
histopatholog
imbalanc
immun
respons
elev
level
cytokin
like
vaccin
anim
model
heat
inactiv
hmpv
also
shown
unsaf
enhanc
level
cytokin
eosinophil
infiltr
lung
vaccin
anim
outcom
vaccin
abovement
inactiv
viru
suggest
develop
better
strategi
gener
hmpv
specif
vaccin
past
year
nanoemuls
base
inactiv
viru
like
rsv
demonstr
yield
safe
vaccin
could
induc
effect
humor
immun
respons
enhanc
viral
clearanc
host
bodi
strategi
along
strategi
like
use
bpl
hydrogen
peroxid
may
also
use
safer
vaccin
develop
hmpv
viral
vector
vector
choic
introduc
express
recombin
protein
target
host
retrovir
vector
express
hmpv
f
protein
shown
induc
strong
protect
immun
respons
differ
subtyp
hmpv
given
intraperiton
rout
mice
model
case
hmpv
g
protein
express
hmpv
f
protein
via
venezuelan
equin
enceph
viru
base
viral
replicon
particl
veevrp
also
demonstr
high
level
immunogen
protect
efficaci
hmpv
infect
african
green
monkey
likewis
recombin
sendai
viru
express
truncat
fusion
protein
hmpv
could
induc
neutral
antibodi
cotton
rat
indic
potenti
recombin
protect
immun
host
hmpv
infect
prior
tang
et
al
success
demonstr
immunogen
protect
efficaci
bovinehuman
chimer
parainfluenza
viru
type
express
hmpv
f
protein
african
green
monkey
apart
viral
vector
bacteri
system
also
shown
act
carrier
viral
gene
palavecino
et
al
demonstr
recombin
bacillu
rbcg
carri
gene
encod
hmpv
p
protein
could
success
express
viral
protein
immun
rbcg
strain
could
induc
protect
immun
mice
model
activ
viru
specif
cell
produc
shown
effect
strategi
manag
hmpv
infect
use
solubl
viral
protein
vaccin
also
induc
host
immun
respons
intramuscular
inject
iscom
matrix
adjuv
solubl
hmpv
f
protein
syrian
golden
hamster
cynomolgu
macaqu
model
effect
induc
cellular
well
humor
immun
respons
differ
subtyp
hmpv
shorter
durat
time
oppos
viral
vector
base
vaccin
prior
cseke
et
al
show
recombin
f
protein
lack
transmembran
domain
express
dna
plasmid
construct
could
induc
protect
immun
respons
cotton
rat
respons
better
full
length
f
protein
without
lung
patholog
type
respons
later
baul
et
al
observ
stimul
inflammatori
respons
hmpv
protein
aert
et
al
demonstr
effect
protein
adjuv
enhanc
immunogen
hmpv
f
protein
elev
cellular
immun
respons
recent
shown
purifi
hmpv
fusion
protein
ectodomain
stabil
prefus
postfus
state
suffici
induc
product
neutral
antibodi
capac
neutral
viru
infect
viruslikeparticl
vlp
success
use
vaccin
candid
import
viral
pathogen
like
human
papilloma
viru
rota
viru
nonpathogen
natur
abil
vlp
expos
viral
protein
nativ
conform
make
one
best
vaccin
strategi
hmpv
vlp
develop
cox
et
al
express
hmpv
fusion
matrix
protein
suspens
adapt
cell
protect
immun
respons
could
gener
mice
model
without
skew
cytokin
respons
vlp
induc
antibodi
respons
also
cell
mediat
immun
respons
hmpv
f
protein
immunogen
enhanc
adjuv
like
titermax
gold
prior
levi
et
al
develop
hmpv
vlp
retrovir
core
hmpv
surfac
protein
f
g
demonstr
efficaci
activ
protect
humor
immun
respons
homolog
well
heterolog
strain
hmpv
mice
model
observ
suggest
f
protein
base
vlp
potent
vaccin
candid
deal
hmpv
infect
live
attenu
virus
live
particl
design
provid
protect
immun
vaccin
recipi
specif
virus
vaccin
includ
virus
weaken
enough
lose
virul
maintain
structur
integr
infect
mimic
natur
infect
allow
host
immun
system
recogn
viru
whole
without
caus
diseas
virus
vaccin
activ
cellular
well
humor
immun
requir
booster
dose
though
type
vaccin
proven
highli
signific
erad
viral
diseas
safeti
issu
efficaci
matter
great
concern
case
mani
viral
infect
vaccin
may
recombin
nonrecombin
nonrecombin
live
attenu
viral
vaccin
gener
viru
cultur
alter
condit
viral
genom
incorpor
sever
mutat
make
viru
avirul
normal
host
physiolog
condit
alter
condit
includ
low
temperatur
condit
chemic
treatment
though
nonrecombin
attenu
virus
activ
immun
system
effici
may
tend
revert
back
virul
virus
insid
host
caus
seriou
diseas
hand
recombin
live
attenu
virus
gener
use
revers
genet
techniqu
virul
factor
either
elimin
modifi
irrevers
suffici
attenu
must
success
live
attenu
viral
vaccin
nonrecombin
cold
adapt
hmpv
viral
vaccin
develop
shown
protect
viral
infect
hamster
model
sever
attempt
also
made
gener
recombin
hmpv
transfect
cultur
anim
cell
viral
cdna
plasmid
encod
viru
specif
rdrp
gener
attenu
hmpv
could
achiev
delet
gene
encod
g
sh
p
protein
replic
viru
lack
g
protein
reduc
viru
lack
g
sh
protein
reduc
compar
wild
type
hmpv
rodent
model
maximum
attenu
achiev
delet
gene
attenu
viru
could
induc
protect
immun
african
green
monkey
model
modif
gene
hmpv
substitut
third
cystein
last
histidin
zinc
bind
motif
also
attenu
viru
attenu
viru
abil
induc
protect
immun
respons
cotton
rat
mutat
sadenosylmethionin
bind
motif
l
protein
remov
nlink
carbohydr
fusion
protein
also
attenu
viru
attenu
viru
provid
protect
homolog
well
heterolog
strain
hmpv
attenu
could
also
attain
replac
hmpv
p
protein
p
protein
avian
mpv
demonstr
recombin
viru
avian
mpv
p
protein
replic
poorli
healthi
adult
mechan
yet
understood
wild
type
recombin
hmpv
codon
optimis
sh
protein
approv
use
parent
viru
develop
live
attenu
hmpv
specif
vaccin
candid
recent
ren
et
al
discuss
signific
protein
base
live
attenu
vaccin
candid
induc
cellular
immun
respons
via
ctl
epitop
also
suppress
hmpv
induc
host
innat
immun
regul
express
mirna
respons
immun
relat
gene
express
strategi
develop
need
valid
effici
vaccin
candid
clinic
trial
develop
success
vaccin
strategi
necessari
identifi
viral
compon
requir
stimul
cellular
humor
immun
respons
host
adapt
immun
respons
target
either
b
cell
cell
epitop
viral
pathogen
sever
studi
done
identifi
immunogen
epitop
hmpv
herd
et
al
identifi
major
histocompat
class
restrict
ctl
epitop
n
g
sh
protein
hmpv
demonstr
administr
epitop
peptid
vaccin
elicit
effector
memori
ctl
respons
along
enhanc
express
type
cytokin
significantli
low
level
type
cytokin
respons
respons
result
reduc
viral
load
immunopatholog
lung
mice
model
recent
hmpv
specif
multiepitop
peptid
design
evalu
protect
efficaci
mice
model
six
b
cell
epitop
four
ctl
epitop
two
th
cell
epitop
hmpv
predict
link
use
defin
spacer
sequenc
design
multiepitop
peptid
mep
express
bacteri
system
shown
vaccin
adjuv
mep
could
induc
strong
humor
well
cell
mediat
immun
respons
balbc
mice
serum
treat
mice
capac
neutral
hmpv
infect
vitro
human
metapneumoviru
import
respiratori
pathogen
capac
caus
seriou
fatal
diseas
human
be
easier
character
viru
similar
anoth
import
respiratori
viru
rsv
approach
manag
hmpv
infect
also
quit
similar
rsv
though
common
antivir
like
ribavirin
ivig
avail
yet
hmpv
specif
therapeut
approach
necessari
effect
challeng
fatal
case
palivizumab
monoclon
antibodi
gener
rsv
effect
hmpv
also
yet
hmpv
specif
monoclon
antibodi
like
develop
success
test
anim
model
test
commerci
like
palivizumab
monoclon
antibodi
may
prove
boon
hmpv
infect
individu
show
seriou
symptom
therapi
hmpv
target
fusion
protein
owe
conserv
natur
among
variou
type
subtyp
viru
certain
peptid
base
fusion
inhibitor
like
test
found
protect
hmpv
likewis
sirna
target
conserv
region
gene
encod
nucleoprotein
phosphoprotein
hmpv
also
shown
protect
effect
viral
infect
among
chemic
inhibitor
sulphat
sialyl
lipid
shown
decreas
viral
titr
infect
individu
also
modul
host
immun
system
antiinflammatori
effect
therapeut
approach
develop
till
date
research
import
effect
therapi
get
approv
made
avail
use
patient
morbid
mortal
due
hmpv
infect
minim
prophylaxi
alway
better
therapi
vaccin
best
approach
control
elimin
pathogen
popul
hmpv
rna
viru
highli
prone
mutat
develop
effect
vaccin
candid
challeng
yet
research
develop
univers
vaccin
candid
underway
inactiv
vaccin
candid
hmpv
yet
success
test
anim
model
lead
enhanc
diseas
sever
upon
subsequ
natur
infect
hand
vaccin
subunit
vaccin
compos
either
purifi
hmpv
fusion
protein
fusion
protein
express
via
differ
viral
bacteri
vector
viz
retrovir
vector
alphaviru
vector
rbcg
etc
could
induc
protect
immun
homolog
well
heterolog
strain
viru
though
short
durat
fusion
protein
base
vlp
combin
certain
adjuv
like
titermax
gold
also
highli
immunogen
protect
viru
though
inactiv
subunit
vaccin
safe
requir
booster
dose
lack
strong
cellular
immun
respons
pose
limit
use
live
attenu
virus
overcom
limit
recombin
approach
develop
live
attenu
viral
vaccin
candid
revers
genet
techniqu
consid
one
best
approach
provid
good
level
attenu
attain
immunogen
maintain
attempt
gener
live
attenu
hmpv
vaccin
candid
success
good
protect
efficaci
rodent
nonhuman
primat
none
yet
enter
clinic
trial
howev
said
though
hmpv
discov
late
signific
advanc
made
interven
viral
infect
